Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Neuer Top-Geologe an Bord - zündet jetzt die nächste Kursrakete?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EEZB | ISIN: US72941H5090 | Ticker-Symbol: XMP0
NASDAQ
04.06.25 | 21:36
0,348 US-Dollar
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur PLUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoPlus Therapeutics GAAP EPS of -$1.19 misses by $0.97, revenue of $1.06M misses by $0.08M12
FrPLUS THERAPEUTICS, INC. - 8-K, Current Report4
FrPlus Therapeutics Inc.: Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights434Company continues to progress both REYOBIQ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:...
► Artikel lesen
FrPLUS THERAPEUTICS, INC. - 10-Q, Quarterly Report2
23.05.Plus Therapeutics recives Nasdaq delinquency notice6
23.05.Plus Therapeutics Inc.: Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q123HOUSTON, May 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today announced it received a delinquency notification letter from Nasdaq on May 21, 2025, which indicated...
► Artikel lesen
PLUS THERAPEUTICS Aktie jetzt für 0€ handeln
19.05.PLUS THERAPEUTICS, INC. - 8-K, Current Report11
14.05.Plus Therapeutics reports progress in CNS cancer therapy14
14.05.Plus Therapeutics verzeichnet Fortschritte bei Therapie für ZNS-Krebs7
14.05.Plus Therapeutics Inc.: Plus Therapeutics' REYOBIQ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)68Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and activation of innate immune responses Updated ReSPECT data...
► Artikel lesen
02.05.PLUS THERAPEUTICS, INC. - 8-K, Current Report4
23.04.Plus Therapeutics beruft Kyle Guse in den Vorstand4
23.04.Plus Therapeutics Inc.: Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors2
18.04.PLUS THERAPEUTICS, INC. - 8-K, Current Report5
15.04.Plus Therapeutics: ReSPECT-LM Data Shows Potential Utility Of REYOBIQ308WASHINGTON (dpa-AFX) - Plus Therapeutics (PSTV) reported the online availability of new data on its lead compound REYOBIQ. The additional data from the Phase 1 ReSPECT-LM dose escalation trial...
► Artikel lesen
15.04.Plus Therapeutics Inc.: Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases6
04.04.Plus Therapeutics files to sell 1.57B shares of common stock for holders5
31.03.PLUS THERAPEUTICS, INC. - 10-K, Annual Report4
28.03.H.C. Wainwright cuts Plus Therapeutics price target to $5.5015
28.03.Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timeline5
Seite:  Weiter >>
63 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1